Last reviewed 2026-05-30 · How we verify

Transdermal Ketoprofen Patch with CHADD

ZARS Pharma Inc. · Phase 2 active Small molecule ✓ Verified May 2026

Transdermal Ketoprofen Patch with CHADD is a Small molecule drug developed by ZARS Pharma Inc.. It is currently in Phase 2 development. Also known as: Matrix Transdermal Ketoprofen/CHADD Sytem.

The Transdermal Ketoprofen Patch with CHADD is a treatment for pain and osteoarthritis, specifically targeting the knee. It works by inhibiting the enzyme cyclooxygenase, which is involved in the production of pain-causing substances.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Transdermal Ketoprofen Patch with CHADD
Also known as	Matrix Transdermal Ketoprofen/CHADD Sytem
Sponsor	ZARS Pharma Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Transdermal Ketoprofen Patch with CHADD CI brief — competitive landscape report
Transdermal Ketoprofen Patch with CHADD updates RSS · CI watch RSS
ZARS Pharma Inc. portfolio CI

Frequently asked questions about Transdermal Ketoprofen Patch with CHADD

What is Transdermal Ketoprofen Patch with CHADD?

Transdermal Ketoprofen Patch with CHADD is a Small molecule drug developed by ZARS Pharma Inc..

Who makes Transdermal Ketoprofen Patch with CHADD?

Transdermal Ketoprofen Patch with CHADD is developed by ZARS Pharma Inc. (see full ZARS Pharma Inc. pipeline at /company/zars-pharma-inc).

Is Transdermal Ketoprofen Patch with CHADD also known as anything else?

Transdermal Ketoprofen Patch with CHADD is also known as Matrix Transdermal Ketoprofen/CHADD Sytem.

What development phase is Transdermal Ketoprofen Patch with CHADD in?

Transdermal Ketoprofen Patch with CHADD is in Phase 2.

Manufacturer: ZARS Pharma Inc. — full pipeline
Also known as: Matrix Transdermal Ketoprofen/CHADD Sytem

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing